ME02484B - Ljudska antitela visokog afiniteta prema ljudskom angiopoietinu-2 - Google Patents
Ljudska antitela visokog afiniteta prema ljudskom angiopoietinu-2Info
- Publication number
- ME02484B ME02484B MEP-2016-155A MEP15516A ME02484B ME 02484 B ME02484 B ME 02484B ME P15516 A MEP15516 A ME P15516A ME 02484 B ME02484 B ME 02484B
- Authority
- ME
- Montenegro
- Prior art keywords
- antibody
- antigen
- amino acid
- binding
- acid sequence
- Prior art date
Links
- 101000924533 Homo sapiens Angiopoietin-2 Proteins 0.000 title claims 2
- 102000047825 human ANGPT2 Human genes 0.000 title claims 2
- 239000000427 antigen Substances 0.000 claims 10
- 102000036639 antigens Human genes 0.000 claims 10
- 108091007433 antigens Proteins 0.000 claims 10
- 239000012634 fragment Substances 0.000 claims 10
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 5
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 5
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 230000033115 angiogenesis Effects 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 208000030533 eye disease Diseases 0.000 claims 2
- 108091008605 VEGF receptors Proteins 0.000 claims 1
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 150000003384 small molecules Chemical class 0.000 claims 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
- A61K38/1866—Vascular endothelial growth factor [VEGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1891—Angiogenesic factors; Angiogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/07—General characteristics of the apparatus having air pumping means
- A61M2205/071—General characteristics of the apparatus having air pumping means hand operated
- A61M2205/073—Syringe, piston type
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Vascular Medicine (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Obesity (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
Claims (8)
1.Izolovane ljudsko antitelo ili njegov fragment koji vezuje antigen koji specifično vezuje ljudski angiopoietin-2 (hAng2) sa Ko manje od 80 pM ali ne ispoljava nikakvo vezivanje na hAng-1 kada se ispituje u ogledu površinske rezonance plazmona i koji obuhvata teški lanac CDR-1 (HCDR1) koji ima sekvencu amino kiseline sa ID BR SEK:4, HCDR-2 sa sekvencom amino kiseline ID BR SEK:6, HCDR-3 sa sekvencom amino kiseline ID BR SEK:8, laki lanaca CDR-1 (LCDR-1) sa sekvencom amino kiseline ID BR SEK:12, LCDR-2 sa sekvencom amino kiseline ID BR SEK:14, i LCDR-3 sa sekvencom amino kiseline ID BR SEK:16.
2. Izolovane antitelo ili fragment za vezivanje antigena prema patentnom zahtevu 1, pri čemu antitelo ili fragment za vezivanje antigena vezuje epitop na hAng-2 (ID BR SEK:518) koji obuhvata: (a) najmanje jednu amino kiselinu izabranu iz F-469, Y-475, i S-480; ili (b) amino kiseline F-469, Y-475, i S-480.
3. Izolovane antitelo ili fragment za vezivanje antigena prema patentom zahtevu 1 ili 2, pri čemu antitelo ili fragment za vezivanje antigena obuhvata HCVR koja ima sekvencu amino kiseline ID BR SEK: 18 i LCVR sa sekvencom amino kiseline ID BR SEK 20.
4.Izolovane antitelo ili fragment za vezivanje antigena prema jednom od patentnih zahteva 1 do 3, pri čemu antitelo ili fragment za vezivanje antigena blokira vezivanje hAng-2 na hTie-2 ali ne blokira značajno vezivanje hAng-1 na hTie-2.
5.Farmaceutsko jedinjenje koje sadrži antitelo ili fragment za vezivanje antigena prema jednom od patentnih zahteva 1 do 4 i farmaceutski prihvatljiv nosač ili razblaživač.
6.Farmaceutsko jedinjenje prema patentnom zahtevu 5 još obuhvata antagonist vaskularnog endotelijalnog faktora rasta (VEGF); pri čemu je VEGF antagonist opciono izabran iz anti-VEGF antitela, inhibitora malog molekula kinaze VEGF receptora i protein fuzije koji suzbija vaskularni endotelijalni faktor rasta (VEGF).
7. Izolovane antitelo ili fragment za vezivanje antigena prema jednom od patentnih zahteva 1 do 4 za upotrebu za lečenje pacijeta koji ima: (a) tumor; ili (b) bolest očiju povezanu sa angiogenezom.
8. Upotreba izolovanog antitela ili fragmenta za vezivanje antigena prema jednom od patentnih zahteva 1 do 4 za proizvodnju leka za upotrebu za lečenje pacijeta koji ima: (a) tumor; ili (b) bolest očiju povezanu sa angiogenezom.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22941809P | 2009-07-29 | 2009-07-29 | |
| US29519410P | 2010-01-15 | 2010-01-15 | |
| PCT/US2010/043295 WO2011014469A1 (en) | 2009-07-29 | 2010-07-27 | High affinity human antibodies to human angiopoietin-2 |
| EP10737224.5A EP2459592B1 (en) | 2009-07-29 | 2010-07-27 | High affinity human antibodies to human angiopoietin-2 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02484B true ME02484B (me) | 2017-02-20 |
Family
ID=42937802
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2016-155A ME02484B (me) | 2009-07-29 | 2010-07-27 | Ljudska antitela visokog afiniteta prema ljudskom angiopoietinu-2 |
Country Status (40)
| Country | Link |
|---|---|
| US (4) | US8987420B2 (me) |
| EP (1) | EP2459592B1 (me) |
| JP (1) | JP5701876B2 (me) |
| KR (1) | KR101781786B1 (me) |
| CN (2) | CN102549015B (me) |
| AR (1) | AR077333A1 (me) |
| AU (1) | AU2010276544B2 (me) |
| BR (1) | BR112012001984B8 (me) |
| CA (1) | CA2769334C (me) |
| CL (1) | CL2012000229A1 (me) |
| CO (1) | CO6491118A2 (me) |
| CR (1) | CR20120086A (me) |
| CY (1) | CY1117695T1 (me) |
| DK (1) | DK2459592T3 (me) |
| EC (1) | ECSP12011694A (me) |
| ES (1) | ES2582405T3 (me) |
| HR (1) | HRP20161043T1 (me) |
| HU (1) | HUE030508T2 (me) |
| IL (1) | IL217680A (me) |
| JO (1) | JO3182B1 (me) |
| MA (1) | MA33534B1 (me) |
| ME (1) | ME02484B (me) |
| MX (1) | MX2012001094A (me) |
| MY (1) | MY156816A (me) |
| NI (1) | NI201200014A (me) |
| NZ (1) | NZ598202A (me) |
| PE (1) | PE20121129A1 (me) |
| PH (1) | PH12012500171A1 (me) |
| PL (1) | PL2459592T3 (me) |
| PT (1) | PT2459592T (me) |
| RS (1) | RS55054B1 (me) |
| RU (1) | RU2545399C2 (me) |
| SG (1) | SG178114A1 (me) |
| SI (1) | SI2459592T1 (me) |
| SM (1) | SMT201600251B (me) |
| TN (1) | TN2012000040A1 (me) |
| TW (1) | TWI527591B (me) |
| UY (1) | UY32812A (me) |
| WO (1) | WO2011014469A1 (me) |
| ZA (1) | ZA201200658B (me) |
Families Citing this family (130)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050144655A1 (en) | 2000-10-31 | 2005-06-30 | Economides Aris N. | Methods of modifying eukaryotic cells |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US20100069614A1 (en) | 2008-06-27 | 2010-03-18 | Merus B.V. | Antibody producing non-human mammals |
| WO2004106375A1 (en) | 2003-05-30 | 2004-12-09 | Merus Biopharmaceuticals B.V. I.O. | Fab library for the preparation of anti vegf and anti rabies virus fabs |
| US20080267971A1 (en) | 2004-12-21 | 2008-10-30 | Green Larry L | Antibodies Directed to Angiopoietin-2 and Uses Thereof |
| US8454960B2 (en) | 2008-01-03 | 2013-06-04 | The Scripps Research Institute | Multispecific antibody targeting and multivalency through modular recognition domains |
| CN115043946A (zh) | 2008-01-03 | 2022-09-13 | 斯克里普斯研究院 | 通过模块识别结构域的抗体靶向 |
| US8557242B2 (en) | 2008-01-03 | 2013-10-15 | The Scripps Research Institute | ERBB2 antibodies comprising modular recognition domains |
| US8557243B2 (en) | 2008-01-03 | 2013-10-15 | The Scripps Research Institute | EFGR antibodies comprising modular recognition domains |
| US8574577B2 (en) | 2008-01-03 | 2013-11-05 | The Scripps Research Institute | VEGF antibodies comprising modular recognition domains |
| JP5596559B2 (ja) | 2008-01-28 | 2014-09-24 | メディミューン リミテッド | 安定化アンジオポエチン２抗体とその用途 |
| US8268314B2 (en) | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
| US8133979B2 (en) | 2008-12-16 | 2012-03-13 | Hoffmann-La Roche Inc. | Antibodies against human angiopoietin 2 |
| EP2564695B1 (en) | 2009-07-08 | 2015-04-15 | Kymab Limited | Animal models and therapeutic molecules |
| US8980268B2 (en) | 2009-07-29 | 2015-03-17 | Regeneron Pharamceuticals, Inc. | Methods for treating cancer by administering an anti-Ang-2 antibody |
| JO3182B1 (ar) | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
| US20120189635A1 (en) | 2009-07-29 | 2012-07-26 | Regeneron Pharmaceuticals, Inc. | Methods for Treating or Preventing Malaria by Administering an Antibody that Specifically Binds Angiopoietin-2 (Ang-2) |
| WO2012009705A1 (en) | 2010-07-15 | 2012-01-19 | Zyngenia, Inc. | Ang-2 binding complexes and uses thereof |
| US9527925B2 (en) | 2011-04-01 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and ANG2 |
| US20130078247A1 (en) * | 2011-04-01 | 2013-03-28 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to dii4 and ang2 |
| WO2012137993A1 (en) * | 2011-04-05 | 2012-10-11 | Neopharm Co., Ltd. | Antibodies against angiopoietins 1 and 2, and their use |
| DK2714738T3 (en) | 2011-05-24 | 2019-01-28 | Zyngenia Inc | MULTIVALENT AND MONOVALENT MULTISPECIFIC COMPLEXES AND THEIR APPLICATIONS |
| JP6333174B2 (ja) | 2011-08-19 | 2018-05-30 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 抗ｔｉｅ２抗体およびその使用 |
| CN103945689B (zh) | 2011-09-19 | 2016-10-19 | 科马布有限公司 | 免疫球蛋白基因多样性的操纵及多抗体治疗剂 |
| CA2791109C (en) | 2011-09-26 | 2021-02-16 | Merus B.V. | Generation of binding molecules |
| MX355877B (es) | 2011-09-30 | 2018-05-03 | Dana Farber Cancer Inst Inc | Peptidos terapeuticos. |
| US9253965B2 (en) | 2012-03-28 | 2016-02-09 | Kymab Limited | Animal models and therapeutic molecules |
| MY164611A (en) * | 2012-01-23 | 2018-01-30 | Regeneron Pharma | Stabilized formulations containing anti-ang2 antibodies |
| TWI613215B (zh) | 2012-02-22 | 2018-02-01 | 再生元醫藥公司 | 抗－大－內皮素－１（ｂｉｇ－ｅｔ－１）抗體及其用途 |
| GB2502127A (en) | 2012-05-17 | 2013-11-20 | Kymab Ltd | Multivalent antibodies and in vivo methods for their production |
| US10251377B2 (en) | 2012-03-28 | 2019-04-09 | Kymab Limited | Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies |
| MX350248B (es) * | 2012-03-30 | 2017-08-31 | Boehringer Ingelheim Int | Moleculas de union a ang2. |
| TWI641687B (zh) | 2012-05-29 | 2018-11-21 | 美商再生元醫藥公司 | 生產細胞株增強子 |
| TW201843172A (zh) * | 2012-06-25 | 2018-12-16 | 美商再生元醫藥公司 | 抗－ｅｇｆｒ抗體及其用途 |
| PE20150361A1 (es) | 2012-07-13 | 2015-03-14 | Roche Glycart Ag | Anticuerpos biespecificos anti-vegf/anti-ang-2 y su utilizacion en el tratamiento de enfermedades vasculares oculares |
| CN104768575B (zh) * | 2012-08-31 | 2017-09-08 | 国立大学法人大阪大学 | 含有vegf特异性表位和/或血管生成素‑2特异性表位的dna疫苗 |
| JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| EA201500370A1 (ru) * | 2012-09-28 | 2015-08-31 | Бёрингер Ингельхайм Интернациональ Гмбх | ФАРМАЦЕВТИЧЕСКИЕ КОМБИНАЦИИ, СОДЕРЖАЩИЕ ДВОЙНЫЕ АНГИОПОЭТИН-2/Dll4 СВЯЗЫВАЮЩИЕ АГЕНТЫ И АНТИ-VEGF-R АГЕНТЫ |
| EP2900260A1 (en) * | 2012-09-28 | 2015-08-05 | Boehringer Ingelheim International GmbH | Pharmaceutical combinations comprising dual angiopoietin-2 / dll4 binders and anti-vegf agents |
| HK1210182A1 (en) | 2012-11-13 | 2016-04-15 | Regeneron Pharmaceuticals, Inc. | Anti-prokineticin receptor (prokr) antibodies and uses thereof |
| GB201223053D0 (en) | 2012-12-20 | 2013-02-06 | Medical Res Council | Receptor |
| JO3405B1 (ar) | 2013-01-09 | 2019-10-20 | Regeneron Pharma | الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها |
| MX2015013163A (es) | 2013-03-15 | 2016-04-04 | Zyngenia Inc | Complejos multiespecificos multivalente y monovalentes y sus usos. |
| US10745483B2 (en) | 2013-03-15 | 2020-08-18 | Dana-Farber Cancer Institute, Inc. | Therapeutic peptides |
| US9788534B2 (en) | 2013-03-18 | 2017-10-17 | Kymab Limited | Animal models and therapeutic molecules |
| US9783593B2 (en) | 2013-05-02 | 2017-10-10 | Kymab Limited | Antibodies, variable domains and chains tailored for human use |
| US11707056B2 (en) | 2013-05-02 | 2023-07-25 | Kymab Limited | Animals, repertoires and methods |
| DK3003038T3 (da) | 2013-06-07 | 2019-11-11 | Scripps Research Inst | 2h-1,2,3-triazolderivater som inhibitorer af fibrose |
| US9828422B2 (en) | 2013-07-29 | 2017-11-28 | Samsung Electronics Co., Ltd. | Anti-Ang2 antibody |
| KR102146845B1 (ko) | 2013-07-30 | 2020-08-21 | 삼성전자주식회사 | 앤지오포이에틴-2에 특이적으로 결합하는 항체 및 그의 용도 |
| KR102196450B1 (ko) | 2013-09-17 | 2020-12-30 | 삼성전자주식회사 | Tie2와 결합을 유도하는 항 Ang2 항체를 포함하는 항암제 |
| AU2014330922A1 (en) | 2013-10-01 | 2016-03-03 | Kymab Limited | Animal models and therapeutic molecules |
| WO2015058048A1 (en) | 2013-10-18 | 2015-04-23 | Regeneron Pharmaceuticals, Inc. | Methods and compositions comprising a combination of a vegf antagonist and an anti-ctla-4 antibody |
| LT3062811T (lt) * | 2013-11-01 | 2019-05-10 | Regeneron Pharmaceuticals, Inc. | Intervencijos angiopoietino pagrindu cerebrinės maliarijos gydymui |
| KR102206029B1 (ko) | 2014-01-27 | 2021-01-20 | 삼성전자주식회사 | Ang-2에 특이적으로 결합하는 항체 및 그의 용도 |
| HRP20191335T1 (hr) | 2014-03-11 | 2019-10-18 | Regeneron Pharmaceuticals, Inc. | Anti-egfrviii antitijela i njihove primjene |
| JP2017510631A (ja) | 2014-03-14 | 2017-04-13 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | 癌に対しｎｋｇ２ｄ経路機能を回復させるためのワクチン組成物および方法 |
| TWI701042B (zh) | 2014-03-19 | 2020-08-11 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
| CN107206067A (zh) * | 2014-05-07 | 2017-09-26 | 免疫医疗有限责任公司 | 使用抗‑ang2抗体的方法 |
| AR100270A1 (es) * | 2014-05-19 | 2016-09-21 | Lilly Co Eli | Anticuerpos ang2 |
| US9994632B2 (en) | 2014-05-26 | 2018-06-12 | Samsung Electronics Co., Ltd. | Humanized or affinity-matured anti Ang-2 antibody and uses thereof |
| AU2015331602A1 (en) | 2014-10-17 | 2017-04-27 | Amgen Inc. | Antibodies directed to angiopoietin-1 and angiopoietin-2 for ocular therapies |
| WO2016073157A1 (en) * | 2014-11-06 | 2016-05-12 | Genentech, Inc. | Anti-ang2 antibodies and methods of use thereof |
| PT3221359T (pt) | 2014-11-17 | 2020-06-23 | Regeneron Pharma | Métodos para o tratamento de tumores usando anticorpos biespecíficos cd3xcd20 |
| US20160144025A1 (en) * | 2014-11-25 | 2016-05-26 | Regeneron Pharmaceuticals, Inc. | Methods and formulations for treating vascular eye diseases |
| AU2015360583B2 (en) | 2014-12-10 | 2020-01-23 | The Scripps Research Institute | Small molecule inhibitors of fibrosis |
| WO2016115218A1 (en) * | 2015-01-14 | 2016-07-21 | The California Institute For Biomedical Research | Antibody drug conjugates for the treatment of immune conditions |
| MX2017009254A (es) * | 2015-01-16 | 2017-10-12 | Juno Therapeutics Inc | Anticuerpos y receptores de antigeno quimerico especificos para ror1. |
| BR112017020149A8 (pt) | 2015-03-27 | 2023-05-02 | Regeneron Pharma | Derivados de maitansinoide, conjugados dos mesmos e métodos de uso |
| JOP20160154B1 (ar) | 2015-07-31 | 2021-08-17 | Regeneron Pharma | أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها |
| KR102677543B1 (ko) * | 2015-09-16 | 2024-06-24 | 아블렉시스, 엘엘씨 | 항-cd115 항체 |
| DK3353212T3 (da) | 2015-09-23 | 2021-12-20 | Regeneron Pharma | Optimerede bispecifikke anti-CD3-antistoffer og anvendelser deraf |
| MA43416A (fr) | 2015-12-11 | 2018-10-17 | Regeneron Pharma | Méthodes pour ralentir ou empêcher la croissance de tumeurs résistantes au blocage de l'egfr et/ou d'erbb3 |
| ES2981791T3 (es) | 2015-12-16 | 2024-10-10 | Regeneron Pharma | Composiciones y métodos para fabricar micropartículas de proteína |
| EA039072B9 (ru) | 2016-01-25 | 2022-02-04 | Регенерон Фармасьютикалз, Инк. | Производные майтанзиноида, их конъюгаты и способы применения |
| EP3411408B1 (en) | 2016-02-02 | 2021-12-08 | Fred Hutchinson Cancer Research Center | Anti-ror1 antibodies and uses thereof |
| EP3468999B1 (en) | 2016-06-10 | 2024-01-10 | Regeneron Pharmaceuticals, Inc. | Anti-gitr antibodies and uses thereof |
| CN116769050A (zh) | 2016-07-20 | 2023-09-19 | 犹他大学研究基金会 | Cd229 car t细胞及其使用方法 |
| MX2019003325A (es) | 2016-09-23 | 2019-08-05 | Regeneron Pharma | Anticuerpos anti-steap2, conjugados anticuerpo-farmaco, y moleculas de fijacion al antigeno biespecificas que se fijan a steap2 y cd3, y usos de estos. |
| EP4273172A3 (en) | 2016-09-23 | 2024-02-28 | Regeneron Pharmaceuticals, Inc. | Bi specific anti-muc16-cd3 antibodies and anti-muc16 drug conjugates |
| US11352425B2 (en) | 2016-11-08 | 2022-06-07 | Absos, Llc | Anti-CD47 antibodies |
| TWI782930B (zh) | 2016-11-16 | 2022-11-11 | 美商再生元醫藥公司 | 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法 |
| KR20190091290A (ko) | 2016-11-29 | 2019-08-05 | 리제너론 파아마슈티컬스, 인크. | Ｐｒｌｒ 양성 유방암 치료 방법 |
| WO2018114728A1 (en) | 2016-12-20 | 2018-06-28 | F. Hoffmann-La Roche Ag | Combination therapy with a bispecific anti-ang2/vegf antibody and a bispecific anti-her2 antibody |
| JP7161494B2 (ja) | 2017-05-06 | 2022-10-26 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ａｐｌｎｒアンタゴニストおよびｖｅｇｆ阻害剤によって眼疾患を治療する方法 |
| US11434303B2 (en) | 2017-06-28 | 2022-09-06 | Bluefin Biomedicine, Inc. | Anti-LY6H antibodies and antibody drug conjugates |
| WO2019149250A1 (zh) * | 2018-02-01 | 2019-08-08 | 南京驯鹿医疗技术有限公司 | 一种结合bcma的嵌合抗原受体(car)及其应用 |
| KR102497171B1 (ko) | 2018-02-20 | 2023-02-08 | 기초과학연구원 | 항-안지오포이에틴-2(Ang2) 항체 및 그의 용도 |
| WO2019197676A1 (en) | 2018-04-13 | 2019-10-17 | Ludwig Institute For Cancer Research Ltd | Heterodimeric inactivatable chimeric antigen receptors |
| MX2020011487A (es) | 2018-04-30 | 2020-12-07 | Regeneron Pharma | Anticuerpos y moleculas biespecificas de union al antigeno que se unen a her2 y/o aplp2, conjugados y usos de estos. |
| CN112399975B (zh) | 2018-06-07 | 2024-05-17 | 基础科学研究院 | 与Tie2结合的抗体及其用途 |
| WO2019235856A1 (ko) | 2018-06-07 | 2019-12-12 | 기초과학연구원 | Tie2에 결합하는 항체 및 이의 용도 |
| WO2020160050A1 (en) | 2019-01-29 | 2020-08-06 | Juno Therapeutics, Inc. | Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ror1) |
| CN113727757A (zh) | 2019-02-21 | 2021-11-30 | 瑞泽恩制药公司 | 使用结合met的抗-met抗体和双特异性抗原结合分子治疗眼癌的方法 |
| JP7177284B2 (ja) * | 2019-02-25 | 2022-11-22 | ファームアブシン・インコーポレイテッド | 抗ａｎｇ２抗体及びその用途 |
| WO2020183245A2 (en) | 2019-03-11 | 2020-09-17 | Janssen Pharmaceutica Nv | ANTI-Vβ17/ANTI-CD123 BISPECIFIC ANTIBODIES |
| WO2020232243A2 (en) * | 2019-05-14 | 2020-11-19 | Froude Jeffrey W | Antibodies to sudan and ebola virus |
| AU2020290971A1 (en) * | 2019-06-14 | 2021-12-23 | Dana-Farber Cancer Institute, Inc. | Antibodies against PD-1 and methods of use thereof |
| US12091460B2 (en) | 2019-06-21 | 2024-09-17 | Regeneron Pharmaceuticals, Inc. | Use of bispecific antigen-binding molecules that bind MUC16 and CD3 in combination with 4-1BB co-stimulation |
| KR20220024594A (ko) | 2019-06-21 | 2022-03-03 | 리제너론 파마슈티칼스 인코포레이티드 | Psma 및 cd3에 결합하는 이중 특이적 항원 결합 분자와 4-1bb 공동 자극의 병용 |
| TWI877179B (zh) * | 2019-06-27 | 2025-03-21 | 德商百靈佳殷格翰國際股份有限公司 | 抗-angpt2抗體 |
| WO2021055350A1 (en) | 2019-09-16 | 2021-03-25 | Regeneron Pharmaceuticals, Inc. | Radiolabeled met binding proteins for immuno-pet imaging |
| US11814428B2 (en) | 2019-09-19 | 2023-11-14 | Regeneron Pharmaceuticals, Inc. | Anti-PTCRA antibody-drug conjugates and uses thereof |
| WO2021123908A1 (en) | 2019-12-20 | 2021-06-24 | Ludwig Institute For Cancer Research Ltd | Car-t cell therapy targeting ngcgm3 |
| CA3166619A1 (en) | 2020-02-28 | 2021-09-02 | Julian Andreev | Bispecific antigen binding molecules that bind her2, and methods of use thereof |
| MX2022010910A (es) | 2020-03-06 | 2022-10-07 | Regeneron Pharma | Anticuerpos anti-gitr y usos de estos. |
| JP2023515707A (ja) * | 2020-04-24 | 2023-04-13 | メモリアル スローン ケタリング キャンサー センター | Ｃｄ１９を標的とするキメラ抗原受容体およびその使用 |
| AU2021268026A1 (en) | 2020-05-08 | 2023-01-19 | Regeneron Pharmaceuticals, Inc. | VEGF traps and mini-traps and methods for treating ocular disorders and cancer |
| BR112023000489A2 (pt) | 2020-07-13 | 2023-03-28 | Regeneron Pharma | Análogos de camptotecina conjugados a um resíduo de glutamina em uma proteína, e seu uso |
| WO2022031882A1 (en) * | 2020-08-06 | 2022-02-10 | Stelexis Therapeutics, Llc | Il-8 antibodies and methods of use thereof |
| KR20230042502A (ko) * | 2020-08-07 | 2023-03-28 | 난징 진스크립트 바이오테크 컴퍼니 리미티드 | 인간 안지오포이에틴-2 항체 및 그 용도 |
| EP4211170A4 (en) | 2020-09-11 | 2024-10-09 | Janssen Biotech, Inc. | METHODS AND COMPOSITIONS FOR MODULATING BETA-CHAIN-MEDIATED IMMUNITY |
| WO2022056197A1 (en) | 2020-09-11 | 2022-03-17 | Janssen Biotech, Inc. | Immune targeting molecules and uses thereof |
| TW202227494A (zh) * | 2020-09-11 | 2022-07-16 | 美商健生生物科技公司 | 多特異性免疫靶向分子及其用途 |
| CA3190569A1 (en) | 2020-10-22 | 2022-04-28 | Christopher Daly | Anti-fgfr2 antibodies and methods of use thereof |
| IL302814A (en) | 2020-11-10 | 2023-07-01 | Regeneron Pharma | Selenium antibody conjugates |
| EP4281475A1 (en) | 2021-01-25 | 2023-11-29 | Regeneron Pharmaceuticals, Inc. | Anti-pdgf-b antibodies and mehods of use for treating pulmonary arterial hypertension (pah) |
| US20240293566A1 (en) | 2021-06-22 | 2024-09-05 | Regeneron Pharmaceuticals, Inc. | ANTI-EGFRvIII ANTIBODY DRUG CONJUGATES AND USES THEREOF |
| JP2024534159A (ja) * | 2021-08-23 | 2024-09-18 | アビラマックス・バイオファーマ・インコーポレイテッド | 導入遺伝子発現のための組成物および方法 |
| CN120329436A (zh) * | 2021-11-26 | 2025-07-18 | 三优生物医药(上海)有限公司 | 抗ang2抗体及其用途 |
| JP2025502147A (ja) | 2022-01-12 | 2025-01-24 | リジェネロン ファーマシューティカルズ，インク． | タンパク質中のグルタミン残基にコンジュゲートしたカンプトテシンアナログおよびその使用 |
| WO2023196903A1 (en) | 2022-04-06 | 2023-10-12 | Regeneron Pharmaceuticals, Inc. | Bispecific antigen-binding molecules that bind and cd3 and tumor associated antigens (taas) and uses thereof |
| EP4518969A1 (en) | 2022-05-02 | 2025-03-12 | Novo Nordisk A/S | Novel anti-angptl3 antibodies suitable for high concentration compositions and subcutaneous administration |
| JP2025519477A (ja) | 2022-06-07 | 2025-06-26 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｔ細胞活性を調節するための多重特異性分子及びその使用 |
| EP4626553A2 (en) | 2022-11-30 | 2025-10-08 | Regeneron Pharmaceuticals, Inc. | Tlr7 agonists and antibody-drug-conjugates thereof |
| CN116003591B (zh) * | 2022-12-12 | 2023-09-19 | 三门峡市眼科医院 | Ang-2抗体及其应用 |
| AU2023407365A1 (en) | 2022-12-21 | 2025-07-31 | Regeneron Pharmaceuticals, Inc. | Prodrugs of topoisomerase i inhibitor for adc conjugations and methods of use thereof |
| CN116789813B (zh) * | 2023-06-27 | 2024-04-26 | 重庆原伦生物科技有限公司 | 一种抗金黄色葡萄球菌α-溶血素的单克隆抗体及其应用 |
| WO2025117727A1 (en) | 2023-11-29 | 2025-06-05 | Regeneron Pharmaceuticals, Inc. | Analogs of quinoxaline/quinoline cytotoxins, linker- payloads, protein-drug conjugates, and uses thereof |
| WO2025186364A1 (en) | 2024-03-06 | 2025-09-12 | Jeansson Marie | Angpt2-targeting antibodies for use in the treatment of fibrotic diseases, particularly kidney disease(s), disorder(s) or injury associated with kidney fibrosis |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5643755A (en) | 1994-10-07 | 1997-07-01 | Regeneron Pharmaceuticals Inc. | Nucleic acid encoding tie-2 ligand |
| US5814464A (en) | 1994-10-07 | 1998-09-29 | Regeneron Pharma | Nucleic acids encoding TIE-2 ligand-2 |
| US20030040463A1 (en) | 1996-04-05 | 2003-02-27 | Wiegand Stanley J. | TIE-2 ligands, methods of making and uses thereof |
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| US7658924B2 (en) | 2001-10-11 | 2010-02-09 | Amgen Inc. | Angiopoietin-2 specific binding agents |
| US7521053B2 (en) | 2001-10-11 | 2009-04-21 | Amgen Inc. | Angiopoietin-2 specific binding agents |
| US7138370B2 (en) | 2001-10-11 | 2006-11-21 | Amgen Inc. | Specific binding agents of human angiopoietin-2 |
| US7205275B2 (en) | 2001-10-11 | 2007-04-17 | Amgen Inc. | Methods of treatment using specific binding agents of human angiopoietin-2 |
| US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
| US7354578B2 (en) * | 2003-06-06 | 2008-04-08 | Regeneron Pharmaceuticals, Inc. | Method of tumor regression with VEGF inhibitors |
| US7850962B2 (en) | 2004-04-20 | 2010-12-14 | Genmab A/S | Human monoclonal antibodies against CD20 |
| SG156668A1 (en) * | 2004-10-19 | 2009-11-26 | Amgen Inc | Angiopoietin-2 specific binding agents |
| US20080267971A1 (en) * | 2004-12-21 | 2008-10-30 | Green Larry L | Antibodies Directed to Angiopoietin-2 and Uses Thereof |
| CA2598833A1 (en) | 2005-03-03 | 2006-09-08 | Curt W. Bradshaw | Anti-angiogenic compounds |
| WO2007033216A2 (en) | 2005-09-12 | 2007-03-22 | Beth Israel Deaconess Medical Center | Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state |
| US20090123474A1 (en) | 2005-12-15 | 2009-05-14 | Astrazeneca Ab | Combination of angiopoietin-2 antagonist and of vegf-a, kdr and/or fltl antagonist for treating cancer |
| AR059066A1 (es) * | 2006-01-27 | 2008-03-12 | Amgen Inc | Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf) |
| PL2374818T3 (pl) | 2006-06-02 | 2013-05-31 | Regeneron Pharma | Przeciwciała o wysokim powinowactwie przeciw ludzkiemu receptorowi IL 6 |
| NO347649B1 (no) | 2006-12-14 | 2024-02-12 | Regeneron Pharma | Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse. |
| JP5596559B2 (ja) | 2008-01-28 | 2014-09-24 | メディミューン リミテッド | 安定化アンジオポエチン２抗体とその用途 |
| US8133979B2 (en) | 2008-12-16 | 2012-03-13 | Hoffmann-La Roche Inc. | Antibodies against human angiopoietin 2 |
| CN102448985B (zh) * | 2009-05-27 | 2015-08-05 | 霍夫曼-拉罗奇有限公司 | 三或四特异性抗体 |
| US8980268B2 (en) | 2009-07-29 | 2015-03-17 | Regeneron Pharamceuticals, Inc. | Methods for treating cancer by administering an anti-Ang-2 antibody |
| JO3182B1 (ar) | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
| US20120189635A1 (en) | 2009-07-29 | 2012-07-26 | Regeneron Pharmaceuticals, Inc. | Methods for Treating or Preventing Malaria by Administering an Antibody that Specifically Binds Angiopoietin-2 (Ang-2) |
| US20160144025A1 (en) * | 2014-11-25 | 2016-05-26 | Regeneron Pharmaceuticals, Inc. | Methods and formulations for treating vascular eye diseases |
-
2010
- 2010-07-01 JO JOP/2010/0227A patent/JO3182B1/ar active
- 2010-07-27 PT PT107372245T patent/PT2459592T/pt unknown
- 2010-07-27 MX MX2012001094A patent/MX2012001094A/es active IP Right Grant
- 2010-07-27 ES ES10737224.5T patent/ES2582405T3/es active Active
- 2010-07-27 PE PE2012000118A patent/PE20121129A1/es active IP Right Grant
- 2010-07-27 MY MYPI2012000326A patent/MY156816A/en unknown
- 2010-07-27 PL PL10737224.5T patent/PL2459592T3/pl unknown
- 2010-07-27 RU RU2012107286/10A patent/RU2545399C2/ru active
- 2010-07-27 WO PCT/US2010/043295 patent/WO2011014469A1/en not_active Ceased
- 2010-07-27 BR BR112012001984A patent/BR112012001984B8/pt not_active IP Right Cessation
- 2010-07-27 US US12/843,905 patent/US8987420B2/en active Active
- 2010-07-27 SG SG2012005591A patent/SG178114A1/en unknown
- 2010-07-27 ME MEP-2016-155A patent/ME02484B/me unknown
- 2010-07-27 HU HUE10737224A patent/HUE030508T2/en unknown
- 2010-07-27 SI SI201031193A patent/SI2459592T1/sl unknown
- 2010-07-27 HR HRP20161043TT patent/HRP20161043T1/hr unknown
- 2010-07-27 DK DK10737224.5T patent/DK2459592T3/en active
- 2010-07-27 KR KR1020127005112A patent/KR101781786B1/ko not_active Expired - Fee Related
- 2010-07-27 AU AU2010276544A patent/AU2010276544B2/en not_active Ceased
- 2010-07-27 CA CA2769334A patent/CA2769334C/en active Active
- 2010-07-27 CN CN201080043266.4A patent/CN102549015B/zh not_active Expired - Fee Related
- 2010-07-27 NZ NZ598202A patent/NZ598202A/en not_active IP Right Cessation
- 2010-07-27 JP JP2012522943A patent/JP5701876B2/ja active Active
- 2010-07-27 RS RS20160638A patent/RS55054B1/sr unknown
- 2010-07-27 CN CN201410475186.6A patent/CN104258390B/zh not_active Expired - Fee Related
- 2010-07-27 PH PH1/2012/500171A patent/PH12012500171A1/en unknown
- 2010-07-27 EP EP10737224.5A patent/EP2459592B1/en active Active
- 2010-07-28 TW TW099124821A patent/TWI527591B/zh not_active IP Right Cessation
- 2010-07-28 AR ARP100102730A patent/AR077333A1/es active IP Right Grant
- 2010-07-29 UY UY0001032812A patent/UY32812A/es unknown
-
2012
- 2012-01-22 IL IL217680A patent/IL217680A/en active IP Right Grant
- 2012-01-25 TN TNP2012000040A patent/TN2012000040A1/en unknown
- 2012-01-25 NI NI201200014A patent/NI201200014A/es unknown
- 2012-01-26 ZA ZA2012/00658A patent/ZA201200658B/en unknown
- 2012-01-26 CL CL2012000229A patent/CL2012000229A1/es unknown
- 2012-02-06 CO CO12019956A patent/CO6491118A2/es active IP Right Grant
- 2012-02-16 MA MA34641A patent/MA33534B1/fr unknown
- 2012-02-20 CR CR20120086A patent/CR20120086A/es unknown
- 2012-02-24 EC ECSP12011694 patent/ECSP12011694A/es unknown
-
2015
- 2015-02-16 US US14/623,089 patent/US9938339B2/en active Active
-
2016
- 2016-06-28 CY CY20161100587T patent/CY1117695T1/el unknown
- 2016-07-27 SM SM201600251T patent/SMT201600251B/it unknown
-
2018
- 2018-02-28 US US15/907,860 patent/US10875911B2/en active Active
-
2020
- 2020-11-25 US US17/104,370 patent/US20210101969A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME02484B (me) | Ljudska antitela visokog afiniteta prema ljudskom angiopoietinu-2 | |
| TWI492757B (zh) | 對人類蛋白酶活化受體－２之高親和性人類抗體 | |
| JP2019151654A (ja) | ヒト抗ｇｒｅｍ１抗体 | |
| JP2018023398A5 (me) | ||
| JP6875275B2 (ja) | Ｌ１ｃａｍ（ｃｄ１７）と結合する抗体などの結合分子 | |
| JP2016519650A5 (me) | ||
| JP2017500018A5 (me) | ||
| JP2017523786A5 (me) | ||
| JP2015120706A5 (me) | ||
| JP2017530722A5 (me) | ||
| TW201444867A (zh) | 抗ｔｎｆ－抗ｉｌ－１７雙特異性抗體 | |
| US8679497B2 (en) | Anti-ferroportin 1 monoclonal antibodies and uses thereof | |
| TW202311284A (zh) | 抗金黃色葡萄球菌溶血素ａ毒素之人類抗體 | |
| HRP20161096T1 (hr) | Antigenski vežući proteini specifični za komponentu p serumskog amiloida | |
| JP2008508858A (ja) | マクロファージ−刺激タンパク質受容体（ｒｏｎ）の阻害 | |
| CN105820245B (zh) | 抗vegf抗体 | |
| JP6231632B2 (ja) | Ａｎｇ２抗体 | |
| JP2015511216A5 (me) | ||
| WO2016109943A1 (zh) | 抗vegf抗体 | |
| CA2745618C (en) | Anti-ferroportin 1 monoclonal antibodies and uses thereof | |
| JP2012510814A5 (me) | ||
| JP2012510802A5 (me) | ||
| JPWO2020193718A5 (me) | ||
| JP2014515743A5 (me) | ||
| JP2010540660A5 (me) |